Posted by Michael Wonder on 31 Jan 2021
New PBS listing brings greater hope for Australians with pulmonary arterial hypertension
31 January 2021 - Australians with a rare, fatal heart condition will soon have subsidised access to a ground-breaking medicine for the first time, thanks to its new listing on the Pharmaceutical Benefits Scheme.
From 1 February, Uptravi (selexipag) will be PBS listed for the first time to treat Pulmonary Arterial Hypertension (PAH), for use in combination with existing PAH therapies.
